RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Interview With EMA’s Eric Abadie

Interview With EMA’s Eric Abadie

Posted 01 March 2011

Dr. Eric Abadie is chairman of the European Medicines Agency (EMA) Committee on Medicinal Products for Human Use (CHMP). He also chairs the agency's Pharmacovigilance Working Party (PhWG) and serves as member of the Committee for Orphan Medicinal Products (COMP). Abadie has more than 25 years of experience in the pharmaceutical industry and is currently the scientific advisor to the director general of Agence française de sécurité sanitaire des produits de santé, France's national Competent Authority. In his roles with CHMP and PhWG, he is at the forefront of EMA's personalized medicine initiative. Regulatory Focus recently had the opportunity to talk with Abadie about the agency's viewpoint on this innovative approach to developing medicinal products.


© 2022 Regulatory Affairs Professionals Society.